Recombinant Vibrio cholerae ghosts as a delivery vehicle for vaccinating against Chlamydia trachomatis

Vaccine

Volumn 21, Issue 15, 2003, Pages 1694-1703

  Eko, Francis O ^a   Lubitz, Werner ^b   McMillan, Lucinda ^a   Ramey, Kiantra ^a   Moore, Terri T ^a   Ananaba, Godwin A ^c   Lyn, Deborah ^a   Black, Carolyn M ^d   Igietseme, Joseph U ^a,d  

^a MOREHOUSE SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF VIENNA   (Austria)

^c CLARK ATLANTA UNIVERSITY   (United States)

^d NATL CENTER FOR INFECTIOUS DISEASES   (United States)

Author keywords

Protection; rVCG MOMP; Vaccine

Indexed keywords

ANTIGEN; IMMUNOLOGICAL ADJUVANT; MEMBRANE PROTEIN; RECOMBINANT VACCINE; RECOMBINANT VIBRIO CHOLERA GHOST VACCINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ARTICLE; CELL PROTECTION; CELLULAR IMMUNITY; CHLAMYDIA TRACHOMATIS; CHLAMYDIASIS; CONTROLLED STUDY; DRUG COST; DRUG DESIGN; DRUG EFFICACY; DRUG MECHANISM; DRUG POTENCY; DRUG SCREENING; GENITAL SYSTEM; GENITAL TRACT INFECTION; HUMAN; HUMAN CELL; IMMUNIZATION; MOUSE; MUCOSA; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; TH1 CELL; VACCINATION; VIBRIO CHOLERAE;

ANIMALS; BACTERIAL VACCINES; CHLAMYDIA INFECTIONS; CHLAMYDIA TRACHOMATIS; DRUG DELIVERY SYSTEMS; FEMALE; HUMANS; MICE; MICE, INBRED BALB C; VACCINES, SYNTHETIC; VIBRIO CHOLERAE;

EID: 0037413959     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0264-410X(02)00677-1     Document Type: Article

References (49)

1. CDC & PHS. Chlamydia trachomatis genital infections - United States, 1995. Morbid Mortal Wkly Rep 1997;46:193-8.
2. Paavonen J., Wolner-Hanssen P. Chlamydia trachomatis: a major threat to reproduction. J. Hum. Reprod. 4:1989;111-124.
3. Schachter J, Grayston JT. Epidemiology of human chlamydial infections. In: Stamm WE, editor. Chlamydial infections. San Francisco/Berkeley, CA; 1998. p. 3-10.
4. Stagg A.J. Vaccines against Chlamydia: approaches and progress. Mol. Med. Today. 4(4):1998;166-173.
5. Grayston J.T., Wang S.-P., Yeh L.J., Kuo C.C. Importance of reinfection in the pathogenesis of trachoma. Rev. Infect. Dis. 7:1985;717-725.
6. Grayston J.T., Wang S.P. The potential for vaccine against infection of the genital tract with Chlamydia trachomatis. Sex Trans. Dis. 5:1978;73-77.
7. Schachter J, Dawson, CR. In: Human chlamydial infections. Littleton, MA: PSG Publishing Company; 1978.
8. Woolridge R.L., Grayston J.T., Chang I.H., Yang C.Y., Cheng K.H. Long-term follow-up of the initial (1959-1960) trachoma vaccine field trial on Taiwan. Am. J. Ophthalmol. 63:1967;1650-1655.
9. Brunham R.C., Peeling R.W. Chlamydia trachomatis antigens: role in immunity and pathogenesis. Infect. Agents Dis. 3:1994;218-233.
10. Kalman S., Mitchell W., Marathe R.et al. Comparative genomes of Chlamydia pneumoniae and C. trachomatis. Nat. Genet. 21(4):1999;385-389.
11. Read T.D., Brunham R.C., Shen C.et al. Genome sequence of Chlamydia trachomatis MoPn and Chlamydia pneumoniae AR39. Nucl. Acids Res. 28(6):2000;1397-1406.
12. Stephens R.S. Chlamydial genomics and vaccine antigen discovery. J. Infect. Dis. 181(Suppl. 3):2000;S521-S523.
13. Stephens R.S., Kalman S., Lammel C.et al. Genome sequence of an obligate intracellular pathogen of humans: Chlamydia trachomatis. Science. 282(5389):1998;754-759.
14. Brunham R.C., Peeling R., Maclean I., McDowell J., Persson K., Osser S. Post-abortal Chlamydia trachomatis salpingitis: correlating risk with antigen-specific serological responses and with neutralization. J. Infect. Dis. 155:1987;749-755.
15. Jones RB, Batteiger BE. Human immune response to Chlamydia trachomatis infections. In: Ward M, editor. Chlamydial infections. London: Cambridge University Press; 1986. p. 423-32.
16. Ward ME. Chlamydial vaccine - future trends. J Infect 1992(Suppl 1):11-26.
17. Batteiger B.E., Rank R.G., Bavoil P.M., Soderberg L.S.F. Partial protection against genital reinfection by immunization of guinea-pigs with isolated outer-membrane proteins of the chlamydial agent of guinea-pig inclusion conjunctivitis. J. Gen. Microbiol. 139:1993;2965-2972.
18. Tuffrey M., Alexander I., Conlan W., Woods C., Ward M. Hetrotypic protection of mice against chlamydial salpingitis and colonization of the lower genital tract with a human serovar F isolate of C. trachomatis by prior immunization with recombinant serovar Ll major outer membrane protein. Eur. J. Immunol. 23:1992;1169-1172.
19. Su H., Parnell M., Caldwell H.D. Protective efficacy of a parenterally administered MOMP-derived synthetic oligopeptide vaccine in a murine model of Chlamydia trachomatis genital tract infection: serum neutralizing IgG antibodies do not protect against genital tract infection. Vaccine. 3(11):1995;1023-1032.
20. Knight S.C., Iqball S., Woods C., Stagg A., Ward M.E., Tuffrey M. A peptide of Chlamydia trachomatis shown to be a primary T-cell epitope in vitro induces cell mediated immunity in vivo. Immunology. 85:1995;8-15.
21. Brunharn R.C., Zhang D.J. Transgene as vaccine for Chlamydia. Am. Heart J. 138:1999;S519-S522.
22. Conlan J.W., Ferris S., Clarke I.N., Ward M.E. Isolation of recombinant fragments of the major outer-membrane protein of Chlamydia trachomatis: their potential as subunit vaccines. J. Gen. Microbiol. 136:1990;2013-2020.
23. Pal S., Barnhart K.M., Wei Q., Abai A.M., Peterson E.M., de la Maza L.M. Vaccination of mice with DNA plasmids coding for the Chlamydia trachomatis major outer membrane protein elicits an immune response but fails to protect against genital challenge. Vaccine. 17(5):1999;459-465.
24. Hayes L.J., Conlan J.W., Everson J.S., Ward M.E., Clarke I.N. Chlamydia trachomatis major outer membrane protein epitopes expressed as fusions with LamB in an attenuated aroa strain of Salmonella typhimurium: their application as potential immunogens. J. Gen. Microbiol. 137:1991;1557-1564.
25. Murdin A.D., Su H., Manning D.S., Klein M.H., Parnell M.J., Caldwell H.D. A poliovirus hybrid expressing a neutralization epitope from the major outer membrane protein of Chlamydia trachomatis is highly immunogenic. Infect. Immun. 61:1993;4404-4414.
26. Szostak M.P., Hensel A., Eko F.O.et al. Bacterial ghosts: non-living candidate vaccines. J. Biotechnol. 44(1-3):1996;161-170.
27. Eko F.O., Witte A., Huter V.et al. New strategies for combination vaccines based on the extended recombinant bacterial ghost system. Vaccine. 17:1999;1643-1649.
28. Witte A., Wanner G., Sulzner M., Lubitz W. Dynamics of PhiX 1 74 protein E mediated lysis of Escherichia coli. Arch. Microbiol. 157:1992;381-388.
29. Ramsey K.H., Soderberg L.S.F., Rank R.G. Resolution of chlamydial genital infection in B-cell-deficient mice and immunity to reinfection. Infect. Immun. 56:1988;1320-1325.
30. Szostak M, Lubitz W. Recombinant bacterial ghosts as multivaccine vehicles. In: Chanock REA, editor. Vaccine 91: modern approaches to new vaccines including prevention of AIDS. Cold Spring Harbor: Cold Spring Harbor Laboratory Press; 1991. p. 409-14.
31. Eko F.O., Mayr U.B., Attridge S.R., Lubitz W. Characterization and immunogenicity of Vibrio cholerae ghosts expressing toxin-coregulated pili. J. Biotechnol. 83:2000;115123.
32. Mermod N., Ramos J., Lehrbach P., Timmis K. Vector for regulated expression of cloned genes in a wide range of gram-negative bacteria. J. Bacteriol. 167:1986;447-454.
33. Eko F.O., Szostak M.P., Wanner G., Lubitz W. Production of Vibrio cholerae ghosts (VCG) by expression of a cloned phage lysis gene: potential for vaccine development. Vaccine. 12:1994;1231-1237.
34. Igietseme J.U., Murdin A. Induction of protective immunity against Chlamydia trachomatis genital infection by a vaccine based on major outer membrane protein lipophilic immune response-stimulating complexes. Infect. Immun. 68(12):2000;6798-6806.
35. Igietseme J.U., Uriri I.M., Kumar S.N.et al. Route of infection that induces a high intensity of gamma interferon-secreting T cells in the genital tract produces optimal protection against Chlamydia trachomatis infection in mice. Infect. Immun. 66(9):1998;4030-4035.
36. Igietseme J.U., Rank R.G. Susceptibility to reinfection after a primary chlamydial genital infection is associated with a decrease of antigen-specific T cells in the genital tract. Infect. Immun. 59:1991;1346-1351.
37. Igietseme J.U., Ramsey K.H., Magee D.M., Williams D.M., Kincy T.J., Rank R.G. Resolution of murine chlamydial genital infection by the adoptive transfer of a biovarspecific, Thl lymphocyte clone. Region. Immunol. 5:1993;317-324.
38. Igietseme J.U., Ananaba G.A., Bolier J. The intercellular adhesion molecule type I is required for rapid activation of T helper type I (Th1) lymphocytes that control early acute phase of genital chlamydial infection in mice. Immunology. 98(4):1999;510-519.
39. Igietseme J.U., Black C.M., Caldwell H.D. Chlamydia vaccines: strategies and status. Biol. Drugs. 16(1):2002;19-35.
40. Murdin A.D., Su H., Klein M.H., Caldwell H.D. Poliovirus hybrids expressing neutralization epitopes from variable domains I and IV of the major outer membrane protein of Chlamydia trachomatis elicit broadly cross-reactive C. trachomatis neutralizing antibodies. Infect. Immun. 63(3):1995;1116-1121.
41. Zhang D.J., Yang X., Berry J., Shen C., McClarty G., Brunham R.C. DNA vaccination with the outer membrane protein gene induces acquired immunity to Chlamydia trachomatis (mouse pneumonitis) infection. J. Infect. Dis. 176:1997;1035-1040.
42. Dong-Ji Z., Yang X., Shen C., Lu H., Murdin A., Brunham R.C. Priming with Chlamydia trachomatis major outer membrane protein (MOMP) DNA followed by MOMP-ISCOM boosting enhances protection and is associated with increased immunoglobulin A and Th I cellular immune responses. Infect. Immun. 68(6):2000;3074-3078.
43. Zhang D.J., Yang X., Shen C., Branham R.C. Characterization of immune responses following intramuscular DNA immunization with the MOMP gene of Chlamydia trachomatis mouse pneumonitis strain. Immunology. 96(2):1999;314-321.
44. De la Maza M.A., De la Maza L.M. A new computer model for estimating the impact of vaccination protocols and its application to the study of Chlamydia trachomatis genital infections. Vaccine. 13(1):1995;119-127.
45. Pal S., Theodor I., Peterson E.M., de la Maza L. Immunization with the Chlamydia trachomatis mouse pneumonitis major outer membrane protein can elicit a protective immune response against a genital challenge. Infect. Immun. 69(10):2001;6240-6247.
46. Rank RG. Models of immunity. In: RS Stephens, editor. Chlamydia: intracellular biology, pathogenesis and immunity. Washington, DC: ASM Press; 1999. p. 239-95.
47. Murdin A.D., Dunn P., Sodoyer R.et al. Use of a mouse lung challenge model to identify antigens protective against Chlamydia pneumoniae lung infection. J. Infect. Dis. 181:2000;S544.
48. Whittum-Hudson J.A., Ann L.L., Saltzman W.M., Prendergast R.A., MacDonald A.B. Oral immunization with an anti-idiotypic antibody to the exoglycolipid antigen protects against experimental Chlamydia trachomatis infection. Nat. Med. 2(10):1996;1116-1121.
49. Eko FO, Lubitz W, Igietseme JU. Immunogenicity of a novel recombinant subunit candidate vaccine against Chlamydia trachomatis. In: Proceedings of the 101st General Meeting of ASM, vol. Ab E-58, Orlando, FL; 2001. p. 341.